TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN . Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n =1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 (TM6SF2) is also reportedly associated with MASLD and sometimes MASH (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, the splice variant rs72613567 in the Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17B13) gene has been identified as protective against MASH, with HSD17B13 potentially contributing to MASH fibrosis by promoting pyrimidine catabolism (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Purcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citation
Cited by
Items 501–600 of 623
Insights into paediatric non‐alcoholic fatty liver disease from genetic variants
Dong, J., Im, Y. R., & Mann, J. P. (2019) · Liver International · doi:10.1111/liv.14020 · Cited by 4
Mori, T., Ozawa, E., Sasaki, R., Shimakura, A., Takahashi, K., Kido, Y., Kanda, Y., Matsuo, S., Tajima, K., Beppu, A., et al. (2024) · JGH Open · doi:10.1002/jgh3.13113 · Cited by 2
A novel human hepatocyte cell line to study PNPLA3-associated steatotic liver disease
Huang, G., Wallace, D. F., & Subramaniam, V. N. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00193.2024 · Cited by 2
Zhou, Q., Liu, P., Zhou, D., Zhang, Y., Li, Z., Li, Z., & Ma, X. (2025) · Medicine · doi:10.1097/md.0000000000043952 · Cited by 4
Kobayashi, T., Yoneda, M., Duseja, A., Fan, J.-G., Nersesov, A., & Nakajima, A. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.010 · Cited by 3
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 9
“Another well-characterized SNP associated with MASLD susceptibility is TM6SF2 rs58543926, encoding an E167K substitution, and it has been associated with increased hepatic steatosis and fibrosis 35,57 .”
Self-citationIlchenko, L. Y., Melnikova, L. I., & Zhuravleva, M. V. (2016) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2016-6-5-45-52 · Cited by 2
“Так, высокое содержание триглицеридов в печени и наличие факторов риска неалкогольного стеатогепатита (НАСГ) выявляют у «носителей» полиморфизмов генов PNPLA3 I148M [22] и TM6SF2 E167К [15].”
Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making
Metwally, M., Eslam, M., & George, J. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0372-8 · Cited by 1
Lammert, F., Jansen, P. L., Lerch, M. M., & Wedemeyer, H. (2023) · De Gruyter eBooks · doi:10.1515/9783110984330 · Cited by 5
Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores
Maccali, C., Pereira, I. V. A., Stefano, J. T., & de Oliveira, C. P. M. S. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00623-6 · Cited by 2
“Liu et al . evaluated a cohort of 99 Northern European Caucasian patients with MASLD-related HCC and compared it with a MASLD cohort with 1,074 individuals [43].”
InfluentialNutrient-Induced Changes of Liver Fat Content in Humans
Kovář, J., & Poledne, R. (2025) · Physiological Research · doi:10.33549/physiolres.935525 · Cited by 2
“Both variants are also associated with an increased risk of disease progression to inflammation and fibrosis [21,22].”
The Natural History of NAFLD: Environmental vs. Genetic Risk Factors
Valenti, L. V. C., & Pelusi, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_7 · Cited by 2
Utilidad práctica de los índices no invasivos en la esteatosis hepática metabólica
Sánchez, C. N. T., Durá-Gil, M., del Río, A. A. D., Pérez, C. M. H., Cuadrado, N. M., de la Cuesta, S. G., Martín, D. P., de Luis, D. A., & de la Fuente, R. A. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.08.001 · Cited by 5
Valoración de la enfermedad por hígado graso no alcohólico desde el laboratorio clínico
López, I. C., & Velasco, J. A. N. (2017) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2017.10.004 · Cited by 4
Li, Z., Lin, M., Liu, C., Chen, Z., Wang, D., Shi, X., Yang, S., & Li, X. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12774 · Cited by 2
Casper, M., Zimmermann, S., Weber, S. N., Arslanow, A., Lammert, F., & Krawczyk, M. J. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.09.015 · Cited by 2
Mandour, M. O., El-Hassan, M., Elkomi, R., & Oben, J. A. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i9.1704 · Cited by 2
Genetic Confounders of Liver Stiffness and Controlled Attenuation Parameter
Rausch, V., Mueller, J. H., & Mueller, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-40542-7_27 · Cited by 2
Can genetic influence in non‐alcoholic fatty liver disease be ignored?
Liu, Y., Day, C. P., & Anstee, Q. M. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch11 · Cited by 2
Self-citationNon-Alcoholic Fatty Liver Disease and Steatohepatitis
Govaere, O., & Anstee, Q. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00265-0 · Cited by 2
Self-citationHepatische Steatosen: Differenzialdiagnostik und aktuelle Aspekte
Canbay, A. E., Gerken, G., & Bechmann, L. P. (2016) · Der Internist · doi:10.1007/s00108-016-0112-0 · Cited by 4
Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease
Salikova, S. P., & Сергеевна, И. Е. (2020) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-183-11-62-69 · Cited by 1
MetALD: new insights and unraveling therapeutic potential
Feng, Y., Han, P., Liu, T., & Gao, Y. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.65 · Cited by 1
Hirai, A., Yoneyama, Y., Assi, I., Osonoi, S., Sakai, S., Ohtsu, K., & Takebe, T. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100774 · Cited by 2
“39,42 Genome-edited iPSCs and associated differentiation protocols developed in this study will be applicable to multicellular liver organoids that include nonparenchymal populations 24,43–45 with zonation feature, 46 serving as a valuable investigative tool for interrogating dissociated impacts on…”
Wang, Q., Guo, J., Liu, S., Cao, X., Guo, Z., Rui, L., Zheng, L., & Wang, C. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342697 · Cited by 3
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 6
Current therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 7
“For instance, a polygenic risk score combining five risk variants ( PNPLA3 (rs738409) 40,41 , TM6SF2 (rs58542926) 14,42 , GCKR (rs1260326), MBOAT7 (rs641738) 43,44 ) and a protective variant in HSD17B13 (rs72613567) 29 ), can identify up to a 12-fold increased risk of advanced fibrosis and a 9-fold…”
Self-citationRobertson, C. L., Sarkar, D., & Sanyal, A. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-34214-6_18 · Cited by 1
Genome Editing and Fatty Liver
Hayat, U., Siddiqui, A. A., Farhan, M. L., Haris, A., & Hameed, N. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_13 · Cited by 1
Huang, H. Y. R., Awuah, W. A., Garg, T., Ng, J. C., Mehta, A., Ramamoorthy, K., Kalmanovich, J. B., & Hasan, M. M. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000743 · Cited by 2
Kreimeyer, H., Vogt, K., Götze, T., Best, J., Götze, O., Weigt, J., Kahraman, A., Özcürümez, M. K., Kälsch, J., Syn, W., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071180 · Cited by 1
“Non-alcoholic fatty liver disease (NAFLD) has a prevalence of nearly 25% worldwide [1–3] and eventually progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and finally hepatocellular carcinoma (HCC).”
BackgroundInfluentialPraxisorientierte Strategien für Screening, Diagnostik und Therapie der NAFLD
Kreimeyer, H., Manka, P. P., & Canbay, A. E. (2023) · Gastro-News · doi:10.1007/s15036-023-3265-4 · Cited by 1
A review: Alcoholic liver disease pathophysiology, current molecular and clinical perspectives
Waghmare, G. R., Katekar, V. A., & Deshmukh, S. P. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.25.2.0424 · Cited by 2
Demirtaş, C. Ö., Eren, F., Yilmaz, D., Özdogan, O. C., & Gündüz, F. (2024) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-5474 · Cited by 1
Moolla, Y., & Ramsuran, V. (2024) · Liver international communications. · doi:10.1002/lci2.70006 · Cited by 1
Reisberg, S., Galwey, N. W., Avillach, P., Sahlqvist, A., Kolberg, L., Mägi, R., Esko, T., Vilo, J., & James, G. (2019) · International Journal of Immunogenetics · doi:10.1111/iji.12413 · Cited by 1
“…2013; Chen et al., 2013; Donati et al., 2016; Dongiovanni et al., 2013; Hardy, Anstee, & Day, 2015; Kitamoto et al., 2014; Kozlitina et al., 2014; Liu et al., 2014; Mancina et al., 2016; Melén et al., 2011; Moffatt et al., 2010; Petit et al., 2016; Petta et al., 2016; Ravi Kanth, Sasikala,…”
A Novel Phosphoinositide-3-kinase Adapter Protein 1 Gene Missense Mutation in Familial Cirrhosis
Philips, C. A., Agarwal, M., Phadke, N., Rajesh, S., Padsalgi, G., Ahamed, R., & Augustine, P. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.02.002 · Cited by 1
Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article
Ahadi, S., Gharekhani, A., & Shiva, A. (2019) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2019.11.004 · Cited by 1
Das klinische Bild der nichtalkoholischen Fettlebererkrankung
Roeb, E. (2020) · Die Gastroenterologie · doi:10.1007/s11377-020-00425-y · Cited by 1
Sidorenko, D. V., Назаров, В. Д., Lapin, S. V., & Emanuel, V. L. (2020) · Medical alphabet · doi:10.33667/2078-5631-2020-5-13-19 · Cited by 3
Brahm, J., Urzua, A. M., Poníachik, J., Cáceres, D., Carreño, L. E., & Venegas, M. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018000700823 · Cited by 1
Genetic predictors and pathophysiological features of non-alcoholic fat liver disease
Smirnova, O. V., Moskalenko, O. L., Каспаров, Э. В., & Каспарова, И. Э. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-15-78-87 · Cited by 1
Saatmann, N., & Zaharia, O. (2021) · Diabetes aktuell · doi:10.1055/a-1646-0208 · Cited by 1
Risk Factors and Hepatocellular Cancer Screening After Hepatitis C Virus Eradication
Bueverov, A. O., Bogomolov, P., & Евгеньевич, С. В. (2021) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2021-17-28-54-60 · Cited by 1
“Особое внимание уделяется НАЖБП как важнейшей причине печеночного канцерогенеза в экономически развитых странах, в том числе у больных на доцирро-тической стадии.”
Nonalcoholic Fatty Liver Disease
Nguyen, V., & Feldstein, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-67293-1.00074-8 · Cited by 2
Precision medicine in diabetes - current trends and future directions. Is the future now?
Szczerbiński, Ł., & Florez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00021-6 · Cited by 1
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Genomic studies in non-alcoholic fatty liver disease
Liu, Y. (2017) · Cited by 1
Self-citationLammert, F. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch41 · Cited by 1
Mei, T., Zhang, J., Tang, S., Guo, H.-Q., Wei, X., Zhang, W., Liu, Y., Liang, S., Fan, Z.-P., Ma, L., et al. (2020) · medRxiv · doi:10.1101/2020.10.11.20210690 · Cited by 1
Self-citationLiver Disease, Nonalcoholic Fatty
Rau, M., & Geier, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65789-6 · Cited by 2
Baechler, S., Saha, L., Factor, V., Chitnis, C., Dhall, A., Becker, D., Marquardt, J. U., & Pommier, Y. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.05.611454 · Cited by 1
“Variants of transmembrane 6 superfamily member 2 (TM6SF2) gene also confer the susceptibility to MASLD 44,45 , and it remains to be determined whether TOP1MT SNPs are present in MASH patients 46 .”
BackgroundLiu, Z., Chen, T., Wang, Y., Zhang, M., Zhou, L., & Zheng, S. (2015) · Hepatology · doi:10.1002/hep.27899
Susceptibility to chronic liver disease
Burza, M. A. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University)
OPINION Nonalcoholic fatty liver disease: new treatments
Hardy, T. L., Anstee, Q. M., & Day, C. P. (2015)
Self-citationRomeo, S., Aghemo, A., Berg, T., Stickel, F., & Valenti, L. V. C. (2015) · Hepatology · doi:10.1002/hep.27901
“In addition, obesity (as indicated by body mass index or waist circumstance) is an important metabolic phenotype that exerts significant influence on hepatic lesions in patients infected with HCV or nonHCV.((2,3)) Indeed, dismissing an adjustment for obesity in the multicovariate analysis also caused inevitable bias i…”
BackgroundGenetic Basis of Alcoholic and Nonalcoholic Fatty Liver Disease
Sookoian, S. C., & Pirola, C. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_7
Sookoian, S. C., & Pirola, C. J. (2014) · Hepatology · doi:10.1002/hep.27655
“Conversely, the 1000 genome project used by Liu et al.(5) contains no phenotypic data and the participants cannot be matched for sex or age.”
InfluentialDelarue, J., & Lallès, J. P. (2016) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2016.09.002
Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease
Kim, H. S., & Cho, Y. K. (2017) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2017.69.6.333 · Cited by 2
Correa, M. L. M. (2017) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/25762
Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma…
Oh, H., & Jun, D. W. (2017) · Journal of Liver Cancer · doi:10.17998/jlc.17.2.117
Human Genomics of Complex Trait Severity
Kleinstein, S. E. (2017)
Obesity-induced hepatic changes during pregnancy
Grilo, L. F. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Genes and NAFLD/NASH Progression
Sharkawy, R. E., George, J., & Eslam, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-37173-9_3 · Cited by 1
ERKRANKUNGEN DER VERDAUUNGSORGANE
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50008-5
Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
Reddy, S. S. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00542-w
Mechanisms of Fibrogenesis in NASH
Pastore, M., Gentilini, A., & Marra, F. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_6
Obesity and NAFLD: Same Problem?
Brodosi, L., Barbanti, F. A., Petroni, M. L., Marchignoli, F., & Marchesini, G. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_1
Zaharia, O. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1247-1420
“Cell Metab 2015; 21: 739– 746 [16] Liu YL, Reeves HL, Burt AD et al.”
BackgroundChen, H., Zhang, Y., Huang, J., Yang, F., Zhang, Y., Guo, T., Mao, Y., Liu, C., Cheng, L., Li, Y., et al. (2021) · Austin Journal of Pathology & Laboratory Medicine · doi:10.26420/austinjpathollabmed.2021.1033
“The susceptible loci that originally were identified to be associated with NAFLD and subsequently were confirmed to be associated with ALD [4,6,9,18,19], suggesting that genetic factors may affect the pathogenesis of these two types of chronic liver disease.”
BackgroundOliveira, A. I. N. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-07072021-105858
Genetic and Environmental Effects on Liver Diseases
Li, Y. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182480991
Obesity and Hepatocellular Carcinoma: Epidemiology and Mechanisms
Akkız, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-78737-0_4
Lim, Y. S. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/139651
Personalised medicine for Non-Alcoholic Fatty Liver Disease
Taylor, A. (2021) · Discovery Research Portal (University of Dundee)
(2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.138
Tada, T., Nishimura, T., Yoshida, M., & Iijima, H. (2022) · Choonpa Igaku · doi:10.3179/jjmu.jjmu.r.201
Weber, S. N., & Lammert, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_8
Genetic Variants Determine Treatment Response in Autoimmune Hepatitis
Zandanell, S., Balcar, L., Semmler, G., Schirmer, A., Leitner, I., Rosenstatter, L., Niederseer, D., Sotlar, K., Schneider, A.-M., Straßer, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030540 · Cited by 1
Cuadrado, N. M. (2022) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/59897
(2023) · De Gruyter eBooks · doi:10.1515/9783110984330-005
Hydes, T., Kennedy, O. J., Glyn‐Owen, K., Buchanan, R. M., Parkes, J., Cuthbertson, D. J., Roderick, P. J., & Byrne, C. D. (2023) · medRxiv · doi:10.1101/2023.08.23.23294514
“two-fold increase in the risk of advanced fibrosis independent of age, diabetes, obesity, or PNPLA3 9 genotype.(17,18) In addition to NAFLD, rs738409 for PNPLA3 and rs58542926 for TM6SF2 have been 10 linked to ArLD, in particular alcohol-related cirrhosis, more advanced liver disease for patients 11 with chronic hepat…”
BackgroundRuamviboonsuk, V., & Chuaypen, N. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.247
Urzua, A. M., Javier Brahm, B., Julio Miranda, B., Laura Carreño, T., & Santos, M. V. (2015) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2015.71350
Molecular pathology of hepatocellular carcinoma
Castellano, J., & Suriawinata, A. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00025-0 · Cited by 1
Gómez, B. B. (2023) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/65186
Non-Alcoholic Fatty Liver Disease and Non-Invasive Methods of Diagnosis
Todorov, K., & Dudrenova, I. (2023) · Actual Nephrology · doi:10.14748/an.v17i1.9225
Wattacheril, J. J., Kleinstein, S. E., Shea, P. R., Wilson, L., Subramanian, G. M., Myers, R. P., Lefkowitch, J. H., Behling, C. A., Xanthakos, S. A., & Goldstein, D. B. (2024) · medRxiv · doi:10.1101/2024.03.02.24303632
Association of PNPLA3, TM6SF2 and HSD17B13 variants with NAFLD risk in HIV and non-HIV individuals
Ruamviboonsuk, V. (2024) · Chulalongkorn Medical Journal · doi:10.56808/2673-060x.5455
Association of TM6SF2 (E167K) with NAFLD in adult Greek people with Type 2 Diabetes Mellitus (T2DM)Preprint
Meritsi, A., Rapti, S., Latsou, D., Koussis, P., Zoumpoulis, P. S., & Thanopoulou, A. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4118620/v1
Lahnsteiner, A., Ellmer, V., Oberlercher, A., Liutkevičiūtė, Z., Schönauer, E., Paulweber, B., Aigner, E. S., & Risch, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.21.585382
Tkachuk, E. A., Seminsky, I. Z., Kozlova, N. M., Malov, S. I., Astakhova, T. A., Abramova, A. N., & Ubusheeva, R. G. (2024) · Baikal Medical Journal · doi:10.57256/2949-0715-2024-2-11-24 · Cited by 2
TM6SF2 as new intestinal lipid player
Tilg, H., & Grander, C. (2025) · Nature Metabolism · doi:10.1038/s42255-024-01156-y
Zabotina, E. E., Хабарова, Ю. А., & Стукова, Н. Ю. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-229-9-96-109
Aung, T. C. Z., Boonkaew, B., Chayanupatkul, M., Poovorawan, K., Chuaypen, N., & Tangkijvanich, P. (2025) · Genes · doi:10.3390/genes16070808 · Cited by 1
“The minor allele of the TM6SF2 rs58542926 variant could lead to severe hepatic steatosis progression in terms of impaired lipid metabolism, and its association is independent of PNPLA3 rs738409’s effect [17].”
MASLD-Related HCC: Trends, Pathogenesis and Current Treatment Options
Li, F., & Wu, Y. (2025) · Advances in Precision Medicine · doi:10.18063/apm.v10i2.896
“The PNPLA3 rs738409 GG genotype is an independent risk factor (OR 5.05, 95% CI 1.47–17.29, P = 0.01) [11] , while TM6SF2’s role remains controversial [12] .”
InfluentialNonalcoholic Fatty Liver Disease
Choi, Y., & Feldstein, A. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00075-6
Yu, F., Fang, Y., Fang, P., & Chen, D. (2025) · Medicine · doi:10.1097/md.0000000000044106
“[23,24] 8] Ni et al indicated that macrophages are a significant pathological factor in the progression from NAFLD to NASH and HCC and that the MIF signaling pathway plays a crucial role in cellular crosstalk at the molecular level.”
Genetic Analysis of Metabolic-associated Steatosis Liver Disease in a Colombian Cohort
Prieto, J. E., Montenegro, D. R. P., Prieto, R. G., Groothuismink, Z. M. A., Córdoba, J. D., Moreno, D., Carreño, M. T., Eslava-Schmalbach, J. H., Debes, J. D., & Boonstra, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103202
Metadata
- Authors
- Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., Donaldson, P., Aithal, G. P., Francque, S., Van Gaal, L., Clement, K., Ratziu, V., Dufour, J.-F., Day, C. P., Daly, A. K., & Anstee, Q. M.
- Affiliations
- Newcastle University (GB)
- Addenbrooke's Hospital (GB)
- University Hospital of Bern (CH)
- Inserm (FR)
- Nottingham University Hospitals NHS Trust (GB)
- Antwerp University Hospital (BE)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Anstee, Quentin M.
- ORCID
- Venue
- Nature Communications
- Published
- 2014-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 4309-4309
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4279183
- OpenAlex
- W2038831349
- Cited by
- 623
- References
- 45
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 50 · 2023: 51 · 2022: 56 · 2021: 61 · 2020: 82 · 2019: 49 · 2018: 50 · 2017: 45 · 2016: 54 · 2015: 50 · 2014: 11
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (FP7/2007–2013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 241762)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- TM6SF2, rs58542926, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, non-synonymous polymorphisms, genetic association, hepatic triglyceride content, neurocan, chromosome 19, steatohepatitis, PNPLA3, disease progression
- MeSH terms
- Adult, Aged, Alleles, Female, Genotype, Heterozygote, Humans, Liver, Liver Cirrhosis, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Cohort Studies, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lectins, C-Type, Neurocan, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.